title: Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.
abstract: BACKGROUND
  Leptomeningeal metastasis (LM) is one of the major problems in the management of metastatic breast cancer; typically, LM has a devastating prognosis and often represents a terminal event. The present study analyzed the clinical features and outcome of LM in patients with breast cancer.
  
  
  METHODS
  The medical records of patients diagnosed with LM from breast cancer at Asan Medical Center, between 2002 and 2012, were reviewed retrospectively.
  
  
  RESULTS
  Of 95 LM patients, 38 (40 %) had an ECOG performance status (PS) ≤ 2, and the median age was 47 years (range 26-72 years). At the time of LM diagnosis, 46 patients (48.4 %) presented with coincidental failure of systemic disease control. Seventy-eight patients (82.1 %) underwent intrathecal (IT) chemotherapy, resulting in cytologic negative conversion in 26 patients, and 46 patients (48.4 %) received systemic chemotherapy. The median overall survival (OS) time was 3.3 months, and 7.8 % of the patients survived for more than 1 year. OS tended to be higher in patients who achieved cytologic negative conversion from IT chemotherapy than in those who did not (4.5 vs. 2.4 months, P = 0.088). Multivariate analysis demonstrated that ECOG PS ≤ 2, controlled extracranial disease at the time of LM diagnosis, and systemic chemotherapy after LM diagnosis were independent factors associated with survival.
  
  
  CONCLUSIONS
  The prognosis of patients with LM from breast cancer is poor. Systemic chemotherapy, in addition to intrathecal chemotherapy, might confer a survival benefit, even after the detection of LM.
authors.affiliation: Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.
authors.forename: Jae-Cheol
authors.initials: JC
authors.lastname: Jo
authors.forename: Myoung Joo
authors.initials: MJ
authors.lastname: Kang
authors.forename: Jeong Eun
authors.initials: JE
authors.lastname: Kim
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Ahn
authors.forename: Kyung Hae
authors.initials: KH
authors.lastname: Jung
authors.forename: Gyungyub
authors.initials: G
authors.lastname: Gong
authors.forename: Hak Hee
authors.initials: HH
authors.lastname: Kim
authors.forename: Seung Do
authors.initials: SD
authors.lastname: Ahn
authors.forename: Su Ssan
authors.initials: SS
authors.lastname: Kim
authors.forename: Byung Ho
authors.initials: BH
authors.lastname: Son
authors.forename: Sei Hyun
authors.initials: SH
authors.lastname: Ahn
authors.forename: Sung-Bae
authors.initials: SB
authors.lastname: Kim
mesh_terms: D000046:Academic Medical Centers; D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000532:radiotherapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007278:Injections, Spinal; D008499:Medical Records; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate